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th thAbstract: 2288.7 µg/L (P < 0.001) at the end of 6 and 12 months 
Background: Iron overload is a predictable and life- of study, respectively. Conclusion: Combined therapy 
threatening complication in patients with thalassemia. significantly decreases serum ferritin level. Study 
Effective and convenient iron chelation remains one of suggests deferiprone as a significant addition to 
the main targets of clinical management of thalassemia support therapy in patients with betathalassemia major 
major. The development of a safe and effective chelator on regular transfusion regimens. 
has been the goal for many years. Aims and Objective: Keywords: Deferiprone, Deferoxamine, Ferritin,It was aimed to compare the effect of deferiprone, Beta-thalassemiadeferoxamine and combination of deferiprone and 
deferoxamine on serum ferritin value in beta- Introduction: 
thalassemia patients. Material and Methods: This Iron overload is a predictable and life-threatening
controlled clinical trial was conducted on 46 major complication in patients with thalassemia and 
beta-thalassemic patients. Fifteen patients in other haematological disorders whose successful 
deferiprone group received deferiprone 75mg/kg/day 
management depends on the regular transfusion
three times a day orally. Nineteen patients in 
of red blood cells. In the absence of effective irondeferoxamine group received deferoxamine 30-50 
chelation therapy, chronic transfusion cause ironmg/kg/day subcutaneously for 8-12 hours/day and 5 
accumulation in the liver, various endocrinedays per week. Twelve patients in combined therapy 
group received deferiprone 75 mg/kg/day three times a organs and the heart. The resulting iron deposits in 
day orally with deferoxamine 30–50 mg/kg subcutane- the target organs then lead to tissue damage and 
ously every other day. Serum ferritin value was complications such as cardiomyopathy, diabetes, 
th
measured at the beginning and at the end of 6 and 12th liver fibrosis and cirrhosis, hypothyroididsm, 
months of study. Results: The mean of serum ferritin hypoparathyroidism, hypogonadism and adrenal 
value in deferiprone group insignificantly increased insufficiency [1]. Consequently, the use of an 
from 2731± 1398.5 µg/L at the beginning to 2788.5 ± effective iron chelator to promote the excretion of 
978.6 µg/L and to 3331.8 ± 1833.9 µg/L at the end of 6th the excess iron from those target organs is 
and 12th months of study, respectively. The mean of essential to prevent the morbidity and early
serum ferritin value in deferoxamine group insignifi­
mortality observed in patients with thalassemia
cantly increased from 2883.5 ± 1598.1 µg/L at the 
major [2-7].beginning to 2935.3 ± 1258.2 µg/L at the end of 6th 
Over the past three decades, iron chelation therapymonth of study and decreased to 2773.8 ± 1216.1 µg/L 
and 12th month of study. The mean of serum ferritin with deferoxamine (DFX) has been shown to 
level in combined therapy group significantly prolong survival, improve growth and sexual 
decreased from 7498.7 ± 3512.9 µg/L at the beginning maturation, and reduce hepatic, cardiac and 
to 4839.9 ± 2698.2 µg/L (P < 0.001) and to 4298.2 ± endocrine dysfunction in iron-overloaded patients 
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[8]. One study suggested that in patients able to 
use a DFX regimen sufficient to control body iron 
load, survival after 15 years of therapy exceeded 
95%. Conversely, in patients who were unable to 
achieve body iron reduction, the probablity of 
survival to age 25 was less than 30% [9]. 
Although DFX can effectively stabilize or reduce 
body iron load, compliance with the demanding 
dosing regimen can be an issue. DFX is generally 
administered five to seven times a week as an 8-to 
12-hour subcutaneous infusion (generally
overnight). This mode of administration is
frequently associated with local irritation at the 
site of the DFX infusion. DFX has also been 
associated with a variety of dose-related
toxicological effects such as visual and auditory 
neurotoxicity, growth retardation and bone
abnormalities. Due to these complications and the 
demanding administration regimen, many
patients are non-compliant with DFX therapy and 
fail to achieve adequate chelation, increasing the 
risk iron-induced complications and early death 
[9-13]. In addition, some patients who remain 
compliant with DFX therapy will nevertheless 
develop cardiac dysfunction and die prematurely 
of cardiac disease [14]. 
Deferiprone (L ) is a bidentate 3-hydroxypyridin­1 
4-one chelating agent that has a high affinity for 
ferric iron [iron (III)], to which it binds to form 
neural 3:1 (deferiprone: iron) complexes that are 
stable over a wide range of pH values [15, 16]. 
That is given as 25 to 33 mg/kg body weight, 
orally, in three doses a day for a total daily dose of 
75 to 100 mg/kg body weight. L1 is rapidly 
absorbed by the upper part of the gastrointestinal 
tract, appearing in the blood within 5 to 10 
minutes [17]. 
The side effects of L1 are agranulocytosis, 
arthropathy, myopathy, zinc deficiency, nausea, 
vomiting, headache, anorexia and liver test 
disorders. Agranulocytosis is the most serious 
complication of deferiprone. It is observed in 
approximately 1% of patients [18]. The potential 
adverse events with L1 are manageable, and for 
patients with iron overload the benefits of reducing 
the risk of serious iron-induced organ damage 
outweigh the risks of chelation therapy [19]. 
Some studies showed that administration of L is a 
suitable way for decreasing iron overload
especially in patients with DFX incompliance 
[20-31]. In another study, serum ferritin value 
decreased in DFX group. It non-significantly 
increased in the L and combined therapy groups1 
[32]. Another studies showed that administration 
of deferiprone with subcutaneous injection of 
deferoxamine is a suitable way for decreasing iron 
overload especially in patients with deferoxamine 
non-compliance [33-37]. Fishers current review 
study (2013) demonstrates that deferiprone is 
indicated for treating iron overload in people with 
thalassaemia major when deferoxamine is
contraindicated or inadequate [38]. El-Beshlawy
et al. studied the effect of deferoxamine,
deferiprone, and a combination of them on the 
serum ferritin level. After 1 year of study, serum 
ferritin level decreased in all groups. Compliance 
was better in combined therapy group. The most 
prevalent complications seen with combined 
therapy were transient arthropathy, nausea and 
vomiting, and combined therapy was considered 
the best therapy option [39]. 
The rate of non-compliance with DFX and 
complications associated with the administration 
are such that the use of an effective drug with 
better compliance is necessary. This study was 
designed to compare the effect of L , DFX and1 
combination of them on serum ferritin value in 
beta-thalassemia patients. 
Material and Methods: 
This controlled clinical trial was conducted 
st stbetween 1 July 2007 and 1 July 2008 in 
hematology-oncology center of Talghani Hospital 
of Golestan University of Medical Sciences in 
Gorgan (a city located in the north of Iran). 
The study was approved by the Golestan
University of Medical Sciences Research and 
ethics Committees. A written informed consent 
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was obtained from all patients and from the parent 
of patients who were less than 18 years old. 
Face-to-face and telephone interviews were
undertaken to ensure regular drug usage and to 
encourage laboratory tests. Drugs side effects 
were specifically asked for and patients were 
advised to report any symptoms indicative of 
infection such as fever, sore throat, and flu-like 
symptoms immediately. 
The combined therapy group included 14 patients 
(7 men, 7 women) and the L group included 201 
patients (7 men, 13 women) randomly selected 
from major beta thalassemia patients referred to 
the center for transfusion. Patients older than 7 
years with negative hepatitis B, C, and HIV tests 
were eligible for enrollment. In combined therapy 
group, L manufactured byAvecina drug company1 
(IRAN) was prescribed 75 mg/kg/ day three times 
a day (TDS) orally with DFX 30–50 mg/kg 
subcutaneously by an infusion pump every other 
day. In L group, L was prescribed 75mg/kg/day1 1 
(TDS) orally. In both group, Complete blood 
count with differential (CBC diff), alanine
aminotransferase (ALT), aspartate amino­
transferase (AST), platelet count (PLT), and 
serum ferritin value were tested at the beginning 
of study. CBC diff and ALT were tested weekly 
until 2 months then every 2 weeks until 2 months 
then monthly on patient's circumstances. 
In response to liver enzymes elevation L dosage1 
was decreased to 50mg/kg/day. After 7-10 days, 
laboratory tests were done again. If this did not 
lead to an improvement or if there was an 
associated neutropenia (neutrophil <1500) or 
thrombocytopenia (PLT<100 000) deferiprone 
would then be stopped until recovery occurred. 
DFX group included 20 patients (9men,
11women) selected from beta-thalassemia
patients that were on DFX therapy before the 
study. DFX was prescribed 30-50 mg/kg by a 
subcutaneous infusion pump for 8-12 hours/day 
and 5 days per week. 
Data inc luding pa t ien ts demographic 
characteristics, primary and periodical laboratory 
tests results, CBC and liver function tests, drug 
side effects such as nausea, vomiting, abdominal 
pain, arthralgia and arthritis were recorded on 
physical exam and interview forms. In each group, 
serum ferritin value was measured in a laboratory 
of Gorgan city by ELISA method at the beginning 
th th
and at end of 6 and 12 months of study. Other 
laboratory tests were done in Talghani hospital 
laboratory. 
Data were analyzed by SPSS software v: 16.0 for 
windows. t-Student, compared t, Wilcoxon and 
Mann-withney tests were used for data analysis. 
Results: 
Finally, a total of 15 patients in L1 group, 19 
patients in DFX group and 12 patients in combined 
therapy group were analyzed. Total of 5 patients 
from L1 group because of arthropathy (n=3), 
nausea, vomiting (n=1) and heart failure (n=1), 1 
patient from DFX group because of disagreement 
and 2 patients from combined therapy group 
because of nausea, vomiting (n=1), and
arthropathy (n=1) were excluded. The mean of age 
[16 ± 6.2 (8-33 y) in L group vs. 16.8 ± 7.1 (8-35 y)1 
in DFX group vs. 17.2 ± 5.3 (10–30 y) in combined 
therapy group] was not significantly different 
between the three groups. Serum ferritin value at 
the beginning of study was not significantly 
different between DFX and L groups (Table 1).1 
In L1 group, the mean of serum ferritin value 
increased non-significantly by 57.5 and 600.8 
th thµg/L at the end of 6 and 12 months of study in 
comparison to the beginning, respectively. The 
rise in serum ferritin (543.3 µg/L ) was non-
significant at the end of 12th month in comparison 
thto 6 month (Table 1).
 
In DFX group, the mean of serum ferritin value 

decreased non-significantly by 109.7 and 161.5 

µg/L at the end of 12th month of study in 

comparison to the beginning and to 6th month, 

respectively. The rise in serum ferritin (51.8 µg/L ) 

was non-significant at the end of 6th month in 

comparison to the beginning (Table 1). 

Ó Journal of Krishna Institute of Medical Sciences University 72 
  
  
      
 
 
  
 
      
     
      
 
  
 
 
 
 
 
 
 
 
  
 
JKIMSU, Vol. 4, No. 1, Jan-Mar 2015 Nargesbeygom Mirbehbahani et. al. 
Table 1: Serum Ferritin Values (µg/l) 
DFX(N=19) L (N=15) DFX+L (N=12)Group Time 1 1 (mean ± SD) (mean ± SD) (mean ± SD) 
Beginning 2883.5 ± 1598.1 2731.0 ± 1398.5* 7498.7 ± 3512.9
 
After 6 months 2935.3 ± 1258.2 2788.5 ± 978.6* 4839.9 ± 2698.2**
 
After 12 months 2773.8 ± 1216.1 3331.8 ± 1833.9* 4298.2 ± 2288.7**,***
 
*p>0.05 when compared with DFX group, ** p<0.001 When compared with values at beginning, 
***
 p>0.05 When compared with values at 6 months after study. 
The mean of serum ferritin level in combined 
therapy group decreased by 2658.8 and 3200 µg/L 
th th(P < 0.001) at the end of 6 and 12 months of 
study in comparison to the beginning,
respectively. There was a non-significant decrease 
of 541.7 µg/L at the end of 12th month of study in 
th
comparison to 6 month (Table 1).
 
No adverse effects were noted in group receiving 

th thDFX. However, at 5 and 7 months of study, 2 
patients out of 19 patients (10.52%) in L group1 
developed mild transient neutropenia and 4 (21%) 
had mild elevation in liver enzymes. Also, a 
transient thrombocytopenia was seen in 5 patients 
(26.32%). By decreasing L1 dosage to
50mg/kg/day all of these side effects were 
removed. So these side effects were mild and 
transient that they be managed. 
Discussion: 
Recently, some studies suggest that use of 
combined therapy with deferoxamine and
deferiprone decreases serum ferritin level of beta­
thalassemic patient by a synergistic effect
[21,27,37,40-42]. Also some studies suggest that 
using of L decrease serum ferritin value of beta­1 
thalassemia patient [20-31]. 

In our study, the mean serum ferritin level in 

combined therapy group decreased from 7498.7 ± 

3512.9 µg/L at the beginning of study to 4839.9 ± 

2698.2 µg/L and to 4298.2 ± 2288.7 µg/L at the 

th th
end of 6 and 12 months of study respectively, 
whereas the mean of serum ferritin value in L1 
group increased non-significantly from 2731 ± 
1398.5 µg/L at the beginning to 2788.5 ± 978.6 
µg/L and to 3331.8 ± 1833.9 µg/L at the end of 6th 
and 12th months of study. The mean of serum 
ferritin value in DFX group increased non-
significantly from 2883.5 ± 1598.1 µg/L at the 
beginning to 2935.3 ± 3940.9 µg/L at the end of 6th 
month and decreased non-significantly to 2773.8 
th± 1216.1 µg/L at the end of 12 month of study. 
There was a rise in serum ferritin values after 6 
months of chelation with oral L1 which is in 
conformity with the results of few earlier workers 
[43,44]. L1 was found to be effective only in 
balancing the iron input due to blood transfusion 
by excreting urinary iron. Few earlier reported 
studies demonstrated a fall in serum ferritin values 
only after at least 18 months of therapy [35-45]. 
The rise in serum ferritin concentration has been 
attributed to the rapid glucoronization of the drug 
in the liver making it ineffective to chelate the 
stored iron in the body [44]. 
Taher et al (2001) reported a significant decrease 
in serum ferritin of patients receiving L after 61 
months. Serum ferritin showed no changes after 
24 months of study. In patients receiving DFX, 
serum ferittin decreased significantly after 6 and 
24 months of study [46]. 
Gomber et al (2004) studied the effect of DFX, L1 
and a combination of them on serum ferritin value. 
After 6 months of study, serum ferritin value 
decreased in DFX group. It non-significantly 
increased in the L and combined therapy groups1 
[32]; whereas Hoffbrand et al. study showed that 
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in patients were on L1 therapy for mean 39.4 
months, serum ferritin value non-significantly 
decreased from initial mean, 2937 µg/L to final 
mean, 2323 µg/L [47]. Aydinok et al. study 
demonstrated that liver iron concentration in L1 
group non-significantly decreased whereas in 
combined therapy group liver iron concentration 
and serum ferritin significantly decreased after 1 
year of study [48]. 
In the study of Kattamis et al. serum ferritin level 
decreased from 4543 to 3279 µg/L after combined 
therapy [36] whereas Hashemieh et al. study 
showed that the mean serum ferritin level of 33 
patients on deferoxamine therapy before the study 
non-significantly increased from 1881 ± 257 to 
2495 ± 384 µg/L after 6-month deferiprone 
therapy[49]. 
Because of deferiprone's lipophilicity, neutral 
charge at pH 7.4 and low molecular weight, it has a 
greater potential than DFX to permeate cell 
membranes and chelate intracellular iron [50]. 
This ability has further elucidated in the Caco-2 
epithelial cell line, in which deferiprone, both free 
and bound to iron, showed significant mobility 
into and out of the cells [51]. Thus it is probable 
that L will be more effective particularly if used in1 
combination with DFX. 
In our study, combined therapy was tolerated very 
well. Only one patient stopped combined therapy 
because of arthropathy and another because of 
nausea and vomiting. In four patients transient 
elevation of liver enzymes occurred but did not 
require cessation of combined therapy. 
Studies have shown that nearly 30% of patients 
receiving L experience drug side effects, but these1 
complications rarely lead to stopping therapy. 
Agranulocytosis is the most serious adverse 
complication associated with L1 use. It is seen in 
approximately 1% of patients [18]. In Gomber's et 
al. study (2004) in L group two patients (9.5%)1 
showed arthropathy and 85.7% showed elevation 
in serum ALT [32]. In order to monitor for this 
complication, the patient's blood should be tested 
every 7-10 days. In our study agranulocytosis was 
not seen. In the combined therapy group, four 
patients developed a mild transient neutropenia 
and liver enzymes elevation but that did not need 
to stop study. In L1 group, A mild transient 
neutropenia and thrombocytopenia was seen in 
two (13.3%) and five (33.3%) patients,
respectively. Nausea and vomiting was seen in one 
patient (6.7%). This complication can be
minimized if the drug is given in divided doses 
after meals.Arthropathy was seen in three patients 
(20%) but settled after stopping L therapy. ALT1 
transient elevation that is another common 
complication of L1 was seen in 26.7% of our 
patients but did not require interruption of therapy. 
Fisher’s study (2013) showed that intensified 
deferoxamine treatment or use of other oral iron 
chelators, or both, remain the established
treatment to reverse cardiac dysfunction due to 
iron overload. Adverse events are increased in 
patients treated with deferiprone compared with 
deferoxamine and in patients treated with
combined deferiprone and deferoxamine
compared with deferoxamine alone [38]. 
Conclusion: 
L and DFX had similar effect on serum ferritin1 
value. L or DFX therapy alone could not decrease1 
serum ferritin values effeciently. Combined
therapy with DFX and L1 showed significant 
decrease in the mean serum ferritin levels. That 
was well tolerated with few significant side 
effects. Owing to the complications and the 
demanding administration regimen, many
patients are non-compliant with DFX therapy and 
fail to achieve adequate chelation, increasing the 
risk of iron-induced complications and early death 
[9–13]; our study suggests L1 as a significant 
addition to support therapy in patients with beta 
thalassemia major on regular DFX transfusion 
regimens. Further trials should compare
therapeutic effects of DFX and L1 particularly in a 
long period of time regimen. 
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